Rubicon Research (RUBICON) investor relations material

Executive summary

• Achieved 51.6% year-over-year revenue growth in Q1 FY27, with broad-based contributions across products and stable pricing driven by specialty and differentiated offerings.

• USD revenue rose 32% year-over-year to $55 million, with strong revenue visibility for upcoming quarters.

• Specialty portfolio contributed 36% of gross profit, underpinned by a robust pipeline and high commercialization rate (88%).

• Two new product approvals received in Q1 FY27, maintaining a strong commercialization pace.

• Unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, were approved by the Board on August 14, 2026.

Financial highlights

• Consolidated revenue from operations for Q1 FY27 was ₹5,343.38 million, up from ₹3,524.94 million in Q1 FY26 and ₹5,139.15 million in Q4 FY26.

• EBITDA increased 64.6% year-over-year to INR 1,312 million, with EBITDA margin improving to 24.6%.

• PAT nearly doubled to INR 848 million, up 95.8% year-over-year.

• EPS (fully diluted) increased 82.2% year-over-year to 5.08.

• Q1 FY27 numbers include consolidation impact from the Arinna acquisition.

Outlook and guidance

• Operating EBITDA margin guidance for FY27 revised upwards to at least 23%, despite anticipated cost pressures from ESOPs, Arinna integration, and pre-revenue site costs.

• Strong revenue visibility and expectation of continued R&D productivity support growth outlook for FY29/30 and beyond.

• No explicit forward-looking guidance was provided, but continued revenue and profit growth is indicated by year-over-year and sequential improvements.